SCHEMBL25203552

SCHEMBL25203552

COc1cc(O)cc(OC)c1C(=O)C=Cc1ccccc1

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.86
KMT2A Q03164 2/20 0.86
NPSR1 Q6W5P4 2/20 0.86
MEN1 O00255 1/20 0.86
KCNA3 P22001 1/20 0.86
TDP1 Q9NUW8 1/20 0.76
TP53 P04637 1/20 0.75
CYP3A4 P08684 1/20 0.75
ATM Q13315 1/20 0.75
HSD17B10 Q99714 1/20 0.75
CYP19A1 P11511 1/20 0.69
CYP2C9 P11712 1/20 0.69
MAOA P21397 1/20 0.69
MAOB P27338 1/20 0.69
CYP2C19 P33261 1/20 0.69
ABCG2 Q9UNQ0 3/20 0.66
SLC5A1 P13866 1/20 0.65
SLC5A2 P31639 1/20 0.65
TNFRSF1A P19438 2/20 0.61
NFKB1 P19838 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25203549 1.00 MAPT (0.86) MAPTKMT2ANPSR1MEN1KCNA3
Cardamomin SCHEMBL1939236 0.93 MAPT (1.00) MAPTKMT2ANPSR1MEN1KCNA3
Cardamomin SCHEMBL25194293 0.93 MAPT (1.00) MAPTKMT2ANPSR1MEN1KCNA3
Cardamomin SCHEMBL449220 0.93 MAPT (1.00) MAPTKMT2ANPSR1MEN1KCNA3
Cardamomin SCHEMBL30891551 0.93 MAPT (1.00) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL4834935 0.89 TDP1 (0.83) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL4834940 0.89 TDP1 (0.83) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL12485779 0.88 ABCG2 (0.85) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL15807406 0.88 MAPT (0.70) MAPTKMT2ANPSR1MEN1KCNA3
SCHEMBL12485774 0.88 ABCG2 (0.85) MAPTKMT2ANPSR1MEN1KCNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MAPT 3297/4885KMT2A 2792/4885NPSR1 4347/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885KMT2A 3188/4885NPSR1 4282/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885KMT2A 3188/4885NPSR1 4282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.